Hua Medicine (Shanghai) Past Earnings Performance
Past criteria checks 0/6
Hua Medicine (Shanghai) has been growing earnings at an average annual rate of 43.5%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 53.6% per year.
Key information
43.5%
Earnings growth rate
48.4%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | 53.6% |
Return on equity | n/a |
Net Margin | -241.8% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?
Nov 17Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects
Aug 28We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth
Jan 06We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow
Aug 02Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Apr 22Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Sep 23We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn
Jun 24Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Mar 22Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook
Feb 21Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year
Jan 25Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business
Dec 21Revenue & Expenses Breakdown
How Hua Medicine (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 109 | -263 | 219 | 220 |
31 Mar 24 | 93 | -237 | 212 | 196 |
31 Dec 23 | 77 | -211 | 204 | 172 |
30 Sep 23 | 82 | -200 | 194 | 150 |
30 Jun 23 | 88 | -189 | 184 | 128 |
31 Mar 23 | 53 | -196 | 164 | 129 |
31 Dec 22 | 18 | -204 | 145 | 130 |
30 Sep 22 | 9 | -234 | 143 | 145 |
30 Jun 22 | 0 | -265 | 140 | 161 |
31 Mar 22 | 0 | -295 | 137 | 174 |
31 Dec 21 | 0 | -326 | 135 | 187 |
30 Sep 21 | 4 | -355 | 137 | 197 |
30 Jun 21 | 9 | -385 | 139 | 207 |
31 Mar 21 | 9 | -389 | 140 | 214 |
31 Dec 20 | 9 | -393 | 140 | 221 |
30 Sep 20 | 16 | -378 | 138 | 244 |
30 Jun 20 | 23 | -363 | 137 | 268 |
31 Mar 20 | 22 | -394 | 142 | 295 |
31 Dec 19 | 22 | -425 | 147 | 322 |
30 Sep 19 | 12 | -1,379 | 144 | 331 |
30 Jun 19 | 3 | -2,333 | 142 | 340 |
31 Mar 19 | 3 | -3,399 | 124 | 309 |
31 Dec 18 | 9 | -3,603 | 100 | 269 |
30 Sep 18 | 13 | -2,578 | 76 | 228 |
30 Jun 18 | 17 | -1,554 | 52 | 186 |
31 Mar 18 | 16 | -440 | 41 | 158 |
31 Dec 17 | 11 | -273 | 31 | 125 |
31 Dec 16 | 1 | -361 | 19 | 75 |
Quality Earnings: 2552 is currently unprofitable.
Growing Profit Margin: 2552 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2552 is unprofitable, but has reduced losses over the past 5 years at a rate of 43.5% per year.
Accelerating Growth: Unable to compare 2552's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2552 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).
Return on Equity
High ROE: 2552's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/21 11:40 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hua Medicine (Shanghai) Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | CLSA |
Bo Li | CLSA |
Ziyi Chen | Goldman Sachs |